Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib – novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled
Neha Agrawal, Mythreyi Narasimhan, Rahul Mojidra, Bhausaheb Bagal, Navin Khattry, Anant Gokarn, Sachin Punattar, Rukmini Govekar · 2026
Read Reduced levels of ITGB1 cause activation of p38MAPK-ERK-LYN axis of BCR::ABL1 signaling despite inactivation of the oncoprotein by imatinib – novel resistance mechanism in blast crisis of chronic myeloid leukemia unraveled by Neha Agrawal, Mythreyi Narasimhan, Rahul Mojidra, Bhausaheb Bagal, Navin Khattry, Anant Gokarn, Sachin Punattar, Rukmini Govekar (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13321628.txt.
Description
Neha Agrawal and co-authors unravel, in 2026, a resistance trick in the blast phase of chronic myeloid leukemia. Drugs that switch off the disease's driver protein fail in most blast-phase patients, and in many the driver is off yet its signaling stays on. Cell studies pointed at an adhesion protein, ITGB1, whose levels fall in resistant cells.
Protein and activity profiling of resistant cells and of cells with the protein knocked down converged on the same detour: a three-step relay that reactivates the driver's pathway from the side. The authors name low ITGB1 as the enabler of this bypass, a fresh target in resistant disease.
Catalog record
| CREATOR | Neha Agrawal, Mythreyi Narasimhan, Rahul Mojidra, Bhausaheb Bagal, Navin Khattry, Anant Gokarn, Sachin Punattar, Rukmini Govekar |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 49 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |